FADS1 Gene Omega3 and Fish Oil Response | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-08 · 5 min read

The Conversion Problem Most Clinicians Miss

Dietary omega-3 fatty acids arrive in two forms: the short-chain ALA from plant sources, and the long-chain EPA and DHA from marine sources. EPA and DHA are the precursors to specialized pro-resolving mediators, resolvins, protectins, and maresins, that actively switch off the inflammatory response once its purpose is served. Without sufficient EPA and DHA conversion, the resolution phase of inflammation is blunted. The signal to stop fighting continues without a counter-signal to stand down.

The rate-limiting enzyme in long-chain fatty acid metabolism is delta-5 desaturase, encoded by FADS1. Its variant rs174537 creates a binary difference in enzyme efficiency: the minor allele reduces FADS1 activity by approximately 15 to 25 percent, lowering the cellular pool of EPA and DHA even in individuals with adequate dietary intake.

What This Means for Anti-Inflammatory Supplementation

The clinical implications are concrete and routinely overlooked. A patient with homozygous minor allele FADS1 genotype who consumes a standard 1-gram EPA/DHA supplement achieves meaningfully lower systemic resolvins than a major allele carrier on the same dose. Their omega-3 index, the percentage of red blood cell membrane EPA plus DHA, remains lower despite equivalent intake.

A 2024 pharmacogenomic study in American Journal of Clinical Nutrition demonstrated that FADS1 rs174537 minor allele homozygotes require approximately 40 percent higher EPA/DHA dosing to achieve the same membrane incorporation as major allele carriers. This is not a population-level trend. It is a patient-specific dosing variable that determines whether the intervention delivers on its anti-inflammatory promise.

Resolution Biology as a Therapeutic Target

The specialized pro-resolving mediators downstream of EPA and DHA do not merely reduce inflammation. They actively drive its resolution, stimulating macrophage efferocytosis, promoting tissue repair, and signaling neutrophil apoptosis. A genome that underproduces these mediators does not simply experience more inflammation. It experiences inflammation that resolves more slowly, more incompletely, and at higher tissue cost.

The GENEFLAMMATION protocol treats FADS1 genotype as a mandatory pharmacogenomic variable in designing omega-3 intervention strategies. Dose, formulation, and the ratio of EPA to DHA are calibrated to the specific conversion efficiency profile the genome reveals, rather than applied uniformly across a patient population whose metabolic handling of the same supplement varies by a factor of nearly two.